Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

8.3%

3 terminated/withdrawn out of 36 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

20 recruiting5 with results

Enrollment Performance

Analytics

N/A
13(61.9%)
Phase 2
6(28.6%)
Phase 1
1(4.8%)
Phase 3
1(4.8%)
21Total
N/A(13)
Phase 2(6)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (36)

Showing 20 of 36 trials
NCT05934851Not ApplicableActive Not Recruiting

A Study Evaluating the Effect of Frozen-Section Directed Excision Surgery on Vulvar Dysplasia

Role: collaborator

NCT02942355Phase 2Active Not Recruiting

Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer

Role: collaborator

NCT07278414Recruiting

Assessing and Addressing Health-Related Social Needs Among Families of Children With Cancer

Role: collaborator

NCT05415358Active Not Recruiting

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

Role: collaborator

NCT04174742Recruiting

Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

Role: collaborator

NCT06523621Phase 2Active Not Recruiting

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

Role: collaborator

NCT06870760Recruiting

Pre-malignant States to Hematologic Malignancies in Firefighters

Role: collaborator

NCT06744712Not ApplicableNot Yet Recruiting

Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients

Role: collaborator

NCT07009093Not ApplicableRecruiting

Utility of a Mobile Application for Young Women With Breast Cancer

Role: collaborator

NCT07203534Not ApplicableRecruiting

ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period

Role: collaborator

NCT03361306Phase 2Completed

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Role: collaborator

NCT07291297Phase 2Recruiting

Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Role: collaborator

NCT06480591Recruiting

Evaluation of the Pathobiology of CALR-mutated MPN Cells

Role: collaborator

NCT06945042Not ApplicableRecruiting

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Role: collaborator

NCT03141359Phase 2Active Not Recruiting

Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC

Role: collaborator

NCT06567704Recruiting

Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study

Role: collaborator

NCT06580106Recruiting

Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML

Role: collaborator

NCT06634381Recruiting

Patient Descriptors Of Cancer-Related Fatigue: A Mixed Methods Pilot Study Of Cancer Survivors

Role: collaborator

NCT06489041Not ApplicableRecruiting

Evaluating Microarray Pharmacogenetic Testing in Cancer Patients

Role: collaborator

NCT06795087Recruiting

Discharge Medication Use Post-Operatively in GU Cancer Patients

Role: collaborator